文献速递淋巴瘤白血病

不列颠哥伦比亚省慢性淋巴细胞白血病和小淋巴细胞淋巴瘤中霍奇金变异型Richter转化的结局

Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
PubMed 文献 · Br J Haematol · 2022-05-14

该研究基于不列颠哥伦比亚省40年间32例霍奇金变异型Richter转化(HvRT)患者的人群队列,分析其特征与生存结局。HvRT诊断后2年无进展生存率和总生存率分别为47%和57%,贫血、乳酸脱氢酶升高、高IPS评分和体能状态差与总生存率显著更差相关;接受治愈性ABVD/ABVD类似方案治疗者2年无进展生存率和总生存率分别为70%和74%。

要点

  • HvRT诊断后2年无进展生存率为47%(95% CI:29%-64%),总生存率为57%(95% CI:38%-72%)。
  • 贫血(p=0.02)、乳酸脱氢酶升高(p=0.04)、高IPS评分(p=0.04)和体能状态差(p=0.001)与总生存率显著更差相关。
  • 接受治愈性ABVD/ABVD类似方案治疗者2年无进展生存率为70%(95% CI:45%-85%),总生存率为74%(95% CI:49%-89%)。

核心结论

  • 在该真实世界人群队列中,HvRT总体临床结局较差;但能够耐受治愈性治疗者的生存与老年新发霍奇金淋巴瘤患者相似。

研究设计与样本

  • 研究为基于人群的队列分析,纳入不列颠哥伦比亚省40年间识别的32例HvRT患者,分析其特征和生存结局。

主要发现

  • 从CLL诊断至HvRT的中位间隔为5.6年(范围0-33.6),其中5例同时诊断。
  • 大多数患者(80%)在HvRT前接受过CLL治疗。
  • HvRT诊断时中位年龄为71岁(范围51-86),多数患者具有高危疾病特征,包括87%为3-4期、65%的国际预后评分(IPS)≥4。
  • HvRT诊断后2年无进展生存率为47%(95% CI:29%-64%),总生存率为57%(95% CI:38%-72%)。
  • 贫血(p=0.02)、乳酸脱氢酶升高(p=0.04)、高IPS评分(p=0.04)和体能状态差(p=0.001)与HvRT诊断后总生存率显著更差相关。

关键数值与推荐

  • 接受治愈性ABVD/ABVD类似方案治疗者2年无进展生存率为70%(95% CI:45%-85%),总生存率为74%(95% CI:49%-89%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hodgkin variant Richter transformation (HvRT) is a rare and challenging complication of chronic lymphocytic leukaemia (CLL) for which information on prognostic factors and treatment approaches remain limited. We analysed characteristics and survival outcomes of a population-based cohort of 32 patients with HvRT identified in British Columbia over a 40-year period. Median interval from CLL diagnosis to HvRT was 5.6 years (range, 0-33.6), with five cases diagnosed concurrently. Most patients (80%) had treatment for CLL prior to HvRT. Median age at HvRT was 71 years (range, 51-86) and the majority of patients had high-risk disease, including stage 3-4 in 87% and International Prognostic Score (IPS) ≥ 4 in 65%. Two-year progression-free (PFS) and overall survival (OS) from HvRT were 47% (95% CI: 29%-64%) and 57% (95% CI: 38%-72%), respectively. OS from HvRT was significantly worse in those with anaemia (p = 0.02), elevated lactate dehydrogenase (p = 0.04), high IPS (p = 0.04), and worse performance status (p = 0.001). For those treated with curative-intent ABVD/ABVD-like therapy, 2-year PFS and OS were 70% (95% CI: 45%-85%) and 74% (95% CI: 49%-89%), respectively. In this real-world population-based cohort, HvRT was associated with poor clinical outcomes overall; however, those able to tolerate curative-intent therapy had similar survival to older patients with de novo HL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhu K, Jamroz A, Huang S, et al. Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia. Br J Haematol. 2022. PMID: 35567407. doi:10.1111/bjh.18241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。